We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Rapid Identification of Pathogens Causing Bacterial Septicemia

By LabMedica International staff writers
Posted on 24 Aug 2010
A molecular based test is now available that will simultaneously identify three Gram-negative bacteria directly from positive blood cultures in less than 90 minutes.

A three-color multiplex assay allows for the identification of Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa from positive blood cultures.
Smears of blood cultures are heat fixed onto microscope slides, a drop of GNR Traffic Light peptide nucleic acid fluorescence in situ hybridization (PNA FISH) probe is added to the smear and then hybridized at 55 °C for 30 minutes. More...


The GNR Traffic Light PNA probe is mixture of a fluorescein-labeled E. coli-specific PNA probe, a fluorescein and tetramethylrhodamine labeled K. pneumoniae-specific
PNA probe and a Texas Red labeled P. aeruginosa-specific PNA probe.

The slides are then washed for 30 minutes at 55 °C. After which the slides are mounted and visualized with a fluorescence microscope with a FITC/Texas Red filter and 60× oil objective. E. coli is identified as green fluorescent cells, K. pneumoniae as yellow and P. aeruginosa as red. The GNR Traffic Light PNA FISH assay is the latest test from AdvanDx (Woburn MA, USA) and is now available in Europe. It is an addition to their easy-to-use, molecular-based PNA FISH diagnostics platform designed to provide rapid, therapy-guiding results enabling clinicians to provide early, effective therapy for patients with Gram-negative bloodstream infections.

Studies show that providing a 24 hours "head start" on appropriate, narrow-spectrum therapy for Gram-negative bloodstream infections may improve clinical outcomes, reduce antibiotic resistance rates, and reduce the incidences of adverse events. GNR Traffic Light PNA FISH will enable microbiology labs to provide clinicians rapid, accurate Gram-negative pathogen identification results in hours, instead of days. Every year, close to 875,000 patients in the USA contract bloodstream infections, leading to over 150,000 deaths. The infection is detected when a culture of the patient's blood turns positive with bacteria or yeast. Rapid and accurate identification of the specific infecting pathogen is crucial to ensure early and appropriate therapy and save patient lives.

Thais T. Johansen, M.B.A., president and CEO of AdvanDx, said, "The GNR Traffic Light PNA FISH test demonstrates AdvanDx's commitment to developing cutting-edge molecular diagnostic products that provide fast results for these serious infections."

Related Links:
AdvanDx


Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.